|

Osimertinib 80 MG Clinical Trials

2 actively recruiting trials

Pipeline

Phase 2: 2

Top Sponsors

  • Shanghai Chest Hospital1
  • Samsung Medical Center1

Indications

  • Lung Cancer2
  • Cancer2
  • Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC)1

Other2 trials

A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC
Phase 2
Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.